Integrin alpha V beta 1

Integrin alpha V beta 1 Overview

English NameIntegrin alpha-V/beta-1Approved Drugs0
Drugs in Clinical Trials5Target Synonym
Highest Development StagePhase 2 Clinical
English NameIntegrin alpha-V/beta-1
Target Synonym
Approved Drugs0
Drugs in Clinical Trials5
Highest Development StagePhase 2 Clinical

Integrin alpha V beta 1 Background

Integrin alpha V beta 1 (αVβ1) is a widely expressed adhesion receptor formed by the non-covalent association of the αV and β1 (CD29) subunits. Its activity is regulated by a conformational shift from a folded, low-affinity state to an extended, high-affinity state, a process triggered by divalent cations and intracellular signaling. As a canonical RGD-binding integrin, it interacts with ligands including vitronectin, fibronectin, and osteopontin. This interaction is central to its role in mediating cell migration, where its modest binding affinity enables the cyclic attachment and detachment necessary for cell movement. Furthermore, αVβ1 is implicated in cellular differentiation and is co-opted by pathogens, such as foot-and-mouth disease virus, for host cell entry.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
IDL-2965IDL-2965Phase 2 ClinicalIndalo Therapeutics IncIdiopathic Pulmonary Fibrosis; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
BexotegrastPLN-74809Phase 2 ClinicalPliant Therapeutics IncCholangitis, Sclerosing; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Respiratory Distress Syndrome, Adult
Details
PLN-1474PLN-1474Phase 1 ClinicalPliant Therapeutics IncLiver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
PLN-101095PLN-101095Phase 1 ClinicalPliant Therapeutics IncSolid tumours
Details
Cu-64-LLP2ACu-64-LLP2A; 64Cu-LLP2APhase 1 ClinicalUniversity Of PittsburghAnemia, Sickle Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma; Waldenstrom Macroglobulinemia
Details

Product Reviews

  • Overview
  • Product List
  • Product Reviews
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland